XML 18 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Changes in Equity - USD ($)
$ in Thousands
Total Stockholder's Equity [Member]
Common Stock
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Treasury Stock [Member]
Deferred Compensation [Member]
Noncontrolling Interests [Member]
Series B Preferred Stock
Total
Beginning Balance at Oct. 31, 2021 $ 642,438 $ 37 $ 1,908,471 $ (1,265,251) $ (819) $ (586) $ 586     $ 642,438
Beginning Balance at (in shares) at Oct. 31, 2021   366,618,693                
Common stock issued, non-employee compensation 100   100             100
Common stock issued, non-employee compensation (in shares)   20,673                
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (260)   (260)             (260)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   60,052                
Share based compensation 1,470   1,470             1,470
Preferred dividends - Series B (800)   (800)             (800)
Effect of foreign currency translation (91)       (91)         (91)
Adjustment for deferred compensation           (64) 64      
Adjustment for deferred compensation (in shares)   (13,232)                
Net income (loss) attributable to redeemable noncontrolling interests 5,496     5,496       $ (5,496)    
Net loss (46,120)     (46,120)           (46,120)
Ending Balance at Jan. 31, 2022 602,233 $ 37 1,908,981 (1,305,875) (910) (650) 650 (5,496)   596,737
Ending Balance at (in shares) at Jan. 31, 2022   366,686,186                
Beginning Balance at Oct. 31, 2021 642,438 $ 37 1,908,471 (1,265,251) (819) (586) 586     642,438
Beginning Balance at (in shares) at Oct. 31, 2021   366,618,693                
Preferred dividends - Series B                 $ (1,600) (1,600)
Effect of foreign currency translation                   (240)
Net loss attributable to noncontrolling interests                   5,405
Net loss                   (76,246)
Ending Balance at Apr. 30, 2022 691,094 $ 39 2,028,206 (1,336,092) (1,059) (718) 718 6,423   697,517
Ending Balance at (in shares) at Apr. 30, 2022   386,608,869                
Beginning Balance at Jan. 31, 2022 602,233 $ 37 1,908,981 (1,305,875) (910) (650) 650 (5,496)   596,737
Beginning Balance at (in shares) at Jan. 31, 2022   366,686,186                
Sale of common stock, net of fees 118,264 $ 2 118,262             118,264
Sale of common stock, net of fees (in shares)   19,896,904                
Common stock issued, non-employee compensation 68   68             68
Common stock issued, non-employee compensation (in shares)   13,002                
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   25,779                
Share based compensation 1,695   1,695             1,695
Preferred dividends - Series B (800)   (800)           (800) (800)
Effect of foreign currency translation (149)       (149)         (149)
Adjustment for deferred compensation           (68) 68      
Adjustment for deferred compensation (in shares)   (13,002)                
Reclass of redeemable non-controlling interest               12,419   12,419
Return of capital to distribution to noncontrolling interest               (496)   (496)
Distribution to noncontrolling interest               (95)   (95)
Net loss attributable to noncontrolling interests                   (91)
Net income (loss) attributable to redeemable noncontrolling interests (91)     (91)       91    
Net loss (30,126)     (30,126)           (30,126)
Ending Balance at Apr. 30, 2022 691,094 $ 39 2,028,206 (1,336,092) (1,059) (718) 718 6,423   697,517
Ending Balance at (in shares) at Apr. 30, 2022   386,608,869                
Beginning Balance at Oct. 31, 2022 684,392 $ 41 2,094,076 (1,407,973) (1,752) (855) 855 7,105   $ 691,497
Beginning Balance at (in shares) at Oct. 31, 2022   405,562,988               405,562,988
Common stock issued, non-employee compensation 68   68             $ 68
Common stock issued, non-employee compensation (in shares)   21,106                
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (314)   (314)             (314)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   169,065                
Share based compensation 2,637   2,637             2,637
Preferred dividends - Series B (800)   (800)             (800)
Effect of foreign currency translation 447       447         447
Adjustment for deferred compensation           (68) 68      
Adjustment for deferred compensation (in shares)   (21,106)                
Reclass of redeemable non-controlling interest               3,030   3,030
Distribution to noncontrolling interest               (106)   (106)
Net loss attributable to noncontrolling interests 2,464     2,464       (2,464)    
Net loss (21,086)     (21,086)           (21,086)
Ending Balance at Jan. 31, 2023 667,808 $ 41 2,095,667 (1,426,595) (1,305) (923) 923 7,565   675,373
Ending Balance at (in shares) at Jan. 31, 2023   405,732,053                
Beginning Balance at Oct. 31, 2022 684,392 $ 41 2,094,076 (1,407,973) (1,752) (855) 855 7,105   $ 691,497
Beginning Balance at (in shares) at Oct. 31, 2022   405,562,988               405,562,988
Preferred dividends - Series B                 (1,600) $ (1,600)
Effect of foreign currency translation                   296
Net loss attributable to noncontrolling interests                   2,072
Net loss                   (54,997)
Ending Balance at Apr. 30, 2023 638,411 $ 41 2,100,724 (1,460,898) (1,456) (923) 923 7,814   $ 646,225
Ending Balance at (in shares) at Apr. 30, 2023   406,738,713               406,738,713
Beginning Balance at Jan. 31, 2023 667,808 $ 41 2,095,667 (1,426,595) (1,305) (923) 923 7,565   $ 675,373
Beginning Balance at (in shares) at Jan. 31, 2023   405,732,053                
Sale of common stock, net of fees 2,663   2,663             2,663
Sale of common stock, net of fees (in shares)   949,438                
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   57,222                
Share based compensation 3,194   3,194             3,194
Preferred dividends - Series B (800)   (800)           $ (800) (800)
Effect of foreign currency translation (151)       (151)         (151)
Distribution to noncontrolling interest               (143)   (143)
Net loss attributable to noncontrolling interests (392)     (392)       392   (392)
Net loss (33,911)     (33,911)           (33,911)
Ending Balance at Apr. 30, 2023 $ 638,411 $ 41 $ 2,100,724 $ (1,460,898) $ (1,456) $ (923) $ 923 $ 7,814   $ 646,225
Ending Balance at (in shares) at Apr. 30, 2023   406,738,713               406,738,713